CD274 and non-small cell lung carcinoma: The KEYNOTE-042 (3) and KEYNOTE-407 (4) studies emphasized the importance of ICIs monotherapy for PD-L1-positive NSCLC patients and the combination of ICIs and chemotherapy for advanced LUSC patients.